Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 8/20 | 0.56 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | XBP1 | P17861 | 1/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13449739 | 0.90 | CA12 (0.70) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL24894114 | 0.82 | CA12 (0.62) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL5851828 | 0.82 | CA12 (0.62) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL13466499 | 0.82 | CA12 (0.62) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL5612177 | 0.81 | RAB9A (0.59) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL3070329 | 0.81 | KMT2A (0.76) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL11913008 | 0.81 | RAB9A (0.67) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL23343705 | 0.81 | RAB9A (0.62) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL23456388 | 0.81 | FPR2 (0.62) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL13754433 | 0.81 | CNR1 (0.66) | CA12CA1CA2CA9RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-02-06 | — | — | US | disclosed |
| WO-2018099952-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | ONCOTYROL CENTER FOR PERSONALIZED CANCER MEDICINE GMBH (AT) | 2018-06-07 | — | — | WO | disclosed |
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944633-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BROAD INSTITUTE, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-04-14 | — | — | US | disclosed |
| US-9120810-B2 | Compounds and methods for the treatment of isocitrate dehydrogenase related diseases | THE BOARD INSTITUTE, INC. (US) | 2015-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | CA12 4739/4885CA1 4114/4885CA2 3782/4885 |
| US-20160102087-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ISOCITRATE DEHYDROGENASE RELATED DISEASES | IDH1, IDH2, IDH3A | CA12 164/4885CA1 276/4885CA2 141/4885 |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | BRD4, BET1, BRD3 | CA12 4741/4885CA1 4192/4885CA2 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.